Search Results
May 20, 2026, 09:50 ET Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
(OTCQB: AVAI), Geron Corporation (NASDAQ: GERN), BioAge Labs, Inc. (NASDAQ: BIOA), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Fate Therapeutics, Inc. (NASDAQ: FATE).
More news about: Market News Updates
Apr 10, 2026, 09:55 ET Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Ocugen, Inc.
More news about: USA News Group
Apr 06, 2026, 13:10 ET Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
transition: Avaí Bio (OTCQB: AVAI), Vericel (NASDAQ: VCEL), Sana Biotechnology (NASDAQ: SANA), Lineage Cell Therapeutics (NYSE-A: LCTX), and Eledon Pharmaceuticals (NASDAQ: ELDN).
More news about: USA News Group
Mar 18, 2026, 10:00 ET A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
physical condition in patients with age-related frailty, including a 63.4-meter improvement in six-minute walk distance. Lineage Cell Therapeutics (NYSE: LCTX) is advancing allogeneic cell therapies for retinal disease and spinal cord injuries through its proprietary AlloSCOPE manufacturing platform. And MannKind
More news about: Equity Insider
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Avant Technologies, Inc. (OTCQB: AVAI), MannKind (NASDAQ: MNKD), Altimmune (NASDAQ: ALT), Lineage Cell Therapeutics (NYSE-A: LCTX), and Arrowhead Pharmaceuticals (NASDAQ: ARWR).
More news about: USA News Group
Dec 16, 2025, 11:53 ET Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
(OTCQB: AVAI), ProKidney Corp. (NASDAQ: PROK), Mesoblast Limited (NASDAQ: MESO), Lineage Cell Therapeutics, Inc. (NYSE-A: LCTX), and BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI).
More news about: Equity Insider